Loading…
A leading global specialty generic pharmaceutical company with a presence in specialty, generics and consumer healthcare products. Manufactures and markets a wide range of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs).
Largest pharmaceutical company in India with significant market share (8.5%) and extensive sales force (~14,000).
Field force expansion in India undertaken in FY24, adding 10% to existing strength, expanding presence in Tier II and Tier III towns. Introduced four innovative products in India (Cequa, Tyvalzi, Rytstat, Lyvelsa).
Operations in approximately 100 countries across six continents, including US (13th largest generic co.), Europe, Emerging Markets, and Rest of World.
Expanding Global Specialty pipeline (e.g., deuruxolitinib NDA filed in US, NidlegyTM filing planned in EU/ANZ). Expanding field force by 9% in key Emerging Markets. Launching Winlevi in Canada and Australia. Commercialising Tyvalzi first in India.
Regulatory approvals (especially USFDA), US generics market pricing dynamics, success of R&D pipeline (particularly specialty), global economic conditions influencing healthcare spending, foreign exchange rate fluctuations.
Strong vertical integration facilitating cost control and supply chain efficiency, diversified revenue streams across specialty generics, pure generics, branded generics, OTC, and APIs, significant scale and market leadership in India, robust R&D capabilities focused on complex and specialty products.
Detailed financial analysis and charts are coming soon!